Firms Vow To Appeal After CMA’s £260m Hydrocortisone Fines In UK
Accord, Advanz And Waymade Respond To Decision By Competition Regulator
Executive Summary
Firms censured by the UK’s CMA competition regulator over illegal deals that drove up the price of hydrocortisone for around a decade have vowed to appeal against the decision and the imposition of fines totaling more than £260m.
You may also be interested in...
UK Competition Watchdog Attacks Tribunal As Hydrocortisone Fines Overturned
UK competition watchdog the CMA says it will be appealing against a tribunal decision that has overturned nearly £100m of fines imposed over anti-competitive deals around hydrocortisone, based on what the CMA criticized as a “fundamentally misconceived procedural point” linked to the cross-examination of witnesses.
Three Remain Liable On UK Liothyronine Price Abuse – But Fines Slimmed On Appeal
Advanz Pharma has failed in its appeal against a £40.9m fine imposed by the UK’s Competition and Markets Authority for its historical pricing practices for liothyronine tablets.
Advanz Hits Back Over £100m+ Fines For UK Liothyronine Pricing
Advanz Pharma has immediately hit back at a decision announced by the UK’s competition regulator to impose fines of more than £100m over the firm’s historical pricing of liothyronine tablets.